South KoreaHealthcare & InsuranceRegulatory changes detected in official sources — tracked continuously by GovToDate's monitoring.
Last detection: 28 September 2026
What changes: From January 1, 2027, a 90% co-payment rate will be applied for exceeding 300 outpatient visits per year. However, children, pregnant women, patients with severe or rare diseases, etc., will be excluded from the co-payment rate application as before.
What changes: From March 1, 2026, the scope of health insurance coverage for the immunotherapy drug 'Imfinzi' (ingredient name: durvalumab) will be expanded. This is expected to alleviate the burden on patients with biliary tract cancer.
What changes: The standard median income has been raised to the maximum level in the second half of 2025, and the dependent ratio for medical aid has been eased (from 30% or 15% to 10%). These measures are intended to strengthen the social safety net.
What changes: Starting January 1, 2027, a 90% co-payment rate will be applied for outpatient visits exceeding 300 times annually. However, children, pregnant women, patients with severe illnesses, and patients with rare diseases will be exempt from this co-payment rate application, as is currently the case.
What changes: Effective March 1, 2026, the scope of health insurance coverage for the immunotherapy drug 'Imfinzi' (ingredient name: durvalumab) will be expanded, easing the burden on patients with biliary tract cancer.
What changes: The long-term care insurance rate for 2026 has been set at 0.9448% of income. Consequently, the average monthly insurance premium per subscriber household is expected to increase by approximately 517 won, from 17,845 won in 2025 to 18,362 won in 2026.
What changes: Managed care rates and coverage standards for manual therapy have been established to reduce patient medical expenses. This includes applying a rate of around 40,000 won per session and limiting the number of sessions to twice a week, with a maximum of 24 times per year.
What changes: The goal is to expand and strengthen the nursing and care integration service from 2 million people in 2022 to 4 million people by 2027.
What changes: The co-payment rate for intra-articular polynuclotide sodium injection for knee joints, a selective benefit item, has been changed from the previous 80% to 90%.
GovToDate reads these official sources continuously and only alerts you about the rules that apply to your situation — your nationality, your qualification, your activity, your countries.
Notify me at launchEvery entry comes from GovToDate's automated detection on the official sources cited, on the date shown. This page presents general information — it is not personalised advice. The official texts prevail.
Titles and summaries are shown in the language of the official source, or in English when that language is not available.
Belgium
China
France
Italy
Japan
Netherlands
Spain